WORCESTER, MA — UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).
UMMS researchers Phillip D. Zamore, PhD, co-director of the RNA Therapeutics Institute, and Guangping Gao, PhD, director of the Gene Therapy Center, are two of the scientific founders.
Voyager Therapeutics will focus on an adeno-associated virus (AAV) approach to gene therapy, which has the potential to transform treatment for a wide range of CNS diseases with one-time therapies that may dramatically improve patients' lives. The company is committed to advancing the field of AAV gene therapy by innovating and investing in areas such as vector optimization and engineering, dosing techniques, and process development and production.
Voyager's scientific and clinical founders are leaders in the fields of AAV gene therapy, expressed RNA interference (RNAi) and neuroscience and include:
Voyager is launching with multiple clinical and preclinical product programs for CNS diseases in dire need of effective new therapies, including a Parkinson's disease program in an ongoing Phase 1b study with its collaborators at UCSF, as well as preclinical programs for a monogenic form of amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia.
Depending on the disease, Voyager's gene therapy products will use either gene replacement or gene knockdown techniques. By significantly increasing or decreasing production of relevant proteins at targeted sites within the CNS, the goal is to address the underlying biology of the disease and make a meaningful difference for patients.
"We believe the time is right for gene therapy, and we have assembled the expertise, technology and strategies to translate the promise of AAV gene therapy into breakthrough treatments for patients with these devastating CNS diseases," said Mark Levin, interim chief executive officer of Voyager and partner at Third Rock. "We are extremely pleased to join forces with UMMS, a world leader in AAV gene therapy research and translation."
Voyager has entered into license and other agreements with UMMS, UCSF and Stanford University to access relevant technology and data, including certain rights to intellectual property related to expressed RNAi technology discovered at UMMS, clinical data related to the Parkinson's disease program from UCSF and certain rights to AAV intellectual property developed at Stanford.
In order to accelerate its research and development efforts, Voyager has also entered into a broad strategic collaboration with UMMS.
"A renaissance is underway in the field of gene therapy, as its long-held promise is fulfilled," said Terence R. Flotte, MD, executive deputy chancellor, dean of the school of medicine and the Celia and Isaac Haidak Professor in Medical Education at UMMS. "Voyager is poised to be a key player in bringing the power of this technology to patients suffering from tragic neurologic diseases."
Over the past 10 years, AAV has emerged as a highly promising and attractive approach to gene therapy. In clinical trials, AAV has been shown to be a safe and effective gene therapy delivery vehicle. Advances in AAV vector development and related dosing techniques that enable widespread gene delivery in the brain and spinal cord have made AAV particularly well-suited for the treatment of CNS diseases. In addition, improvements in related production technology and approaches have made AAV production more easily scalable and cost effective to meet commercial requirements.
Voyager's founding management team has deep expertise and a track record of building exceptional life science companies.
In addition to Mr. Levin, who has more than 30 years of experience building and operating leading biotech companies, the team includes: Philip Reilly, MD, interim chief medical officer, a highly respected clinical geneticist who leads Third Rock's efforts in rare diseases; Steven Paul, MD, interim president of R&D and venture partner at Third Rock, who spent 17 years at Eli Lilly in leadership roles of increasing responsibility, including vice president of discovery research and neuroscience research, and president of the Lilly Research Laboratories, Dr. Paul also served as scientific director of the National Institute of Mental Health, prior to which he was branch chief at the National Institutes of Health (NIH) for 10 years before joining Eli Lilly; Jim Geraghty, interim chief business officer and entrepreneur-in-residence at Third Rock, who spent 20 years at Genzyme in leadership roles across a variety of functions, including as a senior vice president and officer; Dinah Sah, PhD, interim senior vice president of neuroscience and former vice president of research at Alnylam; Jeff Goater, vice president of business development and former managing director at Evercore Partners; Rob Kotin, PhD, vice president of production and former senior investigator at the NIH, where he was the co-inventor of the baculovirus-based AAV production system; and James McLaughlin, head of operations and former associate at Third Rock.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.